research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
Search
for
Sort by
Research
90-120 / 1000+ results research Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
research Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review
Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Baricitinib (Olumiant)
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research Bicalutamide
research Treatment of corticosteroid-refractory alopecia totalis with oral tacrolimus
Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
research Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study
The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
research Tacrolimus monitoring in hair samples of kidney transplant recipients
Hair samples can reliably monitor tacrolimus levels in kidney transplant patients.
research SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Entospletinib effectively prevents eye and skin GVHD in mice.
research Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
research The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata
Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
research Acne keloidalis nuchae in renal transplant patients receiving tacrolimus and sirolimus
Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.
research Topical Tacrolimus (FK506): Treatment Failure in Four Cases of Alopecia Universalis
Topical tacrolimus did not regrow hair in alopecia universalis patients.
research Bimatoprost
research Study of therapeutic comparison of tacrolimus 0.1% and minoxidil 2% in alopecia areata
Minoxidil 2% is more effective than tacrolimus 0.1% for hair regrowth in mild to moderate patchy hair loss, and combining both might give better results.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
research [Effect of tacrolimus on the growth cycle of murine hair follicles].
Tacrolimus helps mice grow hair by activating hair follicles.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Allogeneic Hair Transplantation with Enhanced Survival by Anti-ICAM-1 Antibody with Short-Term Rapamycin Treatment in Nonhuman Primates
Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.
research Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling
Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.
research Drug safety evaluation of exemestane
Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
research Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005% Ointment, and Tacrolimus 0.1% Ointment in Patients with Localized Alopecia Areata: A Triple-Arm Randomized Clinical Study
Calcipotriol is the safest and most effective for hair regrowth in localized alopecia areata.
research Long-Term Clinical Effects, Bioavailability, and Kinetics of Minoxidil in Relation to Renal Function
research Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
research Clobetasol/minoxidil
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients
Golvatinib shows promise as a treatment for Omicron in elderly patients.